Uruguay
Tuberculosis profile
Population  2012 3.4 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.051 (0.048–0.054) 1.5 (1.4–1.6)
Mortality (HIV+TB only) 0.022 (0.018–0.027) 0.64 (0.53–0.78)
Prevalence  (includes HIV+TB) 1.1 (0.49–2.1) 34 (14–61)
Incidence  (includes HIV+TB) 0.93 (0.81–1.1) 27 (24–31)
Incidence (HIV+TB only) 0.14 (0.12–0.16) 4.2 (3.7–4.8)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 432 (57) Relapse 48 (87)
Smear-negative 269 (35) Treatment after failure 0 (0)
Smear-unknown / not done 0 (0) Treatment after default 7 (13)
Extrapulmonary 59 (8) Other 0 (0)
Other 0 (0)      
Total new 760   Total retreatment 55  
           
Other (history unknown) 0        
Total new and relapse 808   Total cases notified 815  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.7 1.6 1.5
Age < 15 5 40 3
Laboratories 2012
Smear (per 100 000 population) <0.1
Culture (per 5 million population) 1.5
Drug susceptibility testing (per 5 million population) 1.5
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 85   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 83  
Retreatment 79  
TB/HIV 2012 Number (%)
TB patients with known HIV status 775 (95)
HIV-positive TB patients 134 (17)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 32 (24)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0 (0–0.79) 2.4 (0.06–13)
MDR-TB cases among notified pulmonary
TB cases
0 (0–6) 1 (0–7)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 466 (88%) 42 (76%) 508
Laboratory-confirmed MDR-TB cases 0 1 1
Patients started on MDR-TB treatment     1
Financing TB control 2013
National TB programme budget (US$ millions) 4.3
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data